Abstract
Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome characterized by seizures, mental retardation, autism, and tumors of the brain, kidney, heart, retina, and skin. TSC is caused by mutations in either TSC1 or TSC2, both of which are tumor suppressor genes. Hamartin, the protein product of TSC1, was found to interact with the ezrin-radixin-moesin family of cytoskeletal proteins and to activate the small GTPase Rho. To determine whether tuberin, the TSC2 product, can also activate Rho, we stably expressed full-length human tuberin in two cell types: MDCK cells and ELT3 cells. ELT3 cells lack endogenous tuberin expression. We found that expression of human tuberin in both MDCK and ELT3 cells was associated with an increase in the amount of Rho-GTP, but not in Rac1-GTP or cdc42-GTP. Tuberin expression increased cell adhesion in both cell types, and decreased chemotactic cell migration in ELT3 cells. In MDCK cells, there was a decrease in the amount of total Focal Adhesion Kinase (FAK) and an increase in the fraction of phosphorylated FAK. These findings demonstrate for the first time that tuberin activates Rho and regulates cell adhesion and migration. Pathways involving Rho activation may have relevance to the clinical manifestations of TSC, including pulmonary lymphangioleiomyomatosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agochiya M, Brunton VG, Owens DW, Parkinson EK, Paraskeva C, Keith WN, Frame MC . 1999 Oncogene 18: 5646–5653
Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, DeClue JE . 2000 Oncogene 19: 6306–6316
Bobak D, Moorman J, Guanzon A, Gilmer L, Hahn C . 1997 Oncogene 15: 2179–2189
Bonifacino J, Dasso M, Harford J, Lippincott-Schwartz J, Yamada K . 2001 Current protocols in cell biology New York: John Wiley and Sons, Inc
Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S, Xu L . 2000 Clin. Cancer Res. 6: 2417–2423
Carsillo T, Astrinidis A, Henske EP . 2000 Proc. Natl. Acad. Sci. USA 97: 6085–6090
Clark EA, Golub TR, Lander ES, Hynes RO . 2000 Nature 406: 532–535
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ . 2001 Am. J. Hum. Genet. 68: 64–80
European chromosome 16 Tuberous Sclerosis Consortium. 1993 Cell 75: 1305–1315
Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, Collard JG . 2000 Eur. J. Cancer 36: 1269–1274
Flinn HM, Ridley AJ . 1996 J. Cell Sci. 109: 1133–1141
Gomez M, Sampson JR, Whittemore VH (eds) . 1999 Tuberous Sclerosis Complex 3rd edn New York: Oxford University Press
Henry KW, Yuan X, Koszewski NJ, Onda H, Kwiatkowski DJ, Noonan DJ . 1998 J. Biol. Chem. 273: 20535–20539
Hodges AK, Li S, Maynard J, Parry L, Braverman R, Cheadle JP, DeClue JE, Sampson JR . 2001 Hum. Mol. Genet. 10: 2899–2905
Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C . 1995 Am. J. Pathol. 146: 1568–1579
Ilic D, Damsky CH, Yamamoto T . 1997 J. Cell Sci. 110: 401–407
Irani C, Goncharova EA, Hunter DS, Walker CL, Panettieri RA, Krymskaya VP . 2002 Am. J. Physiol. Lung Cell. Mol. Physiol. 282: L854–L862
Ito N, Rubin GM . 1999 Cell 96: 529–539
Judson PL, He X, Cance WG, Van Le L . 1999 Cancer 86: 1551–1556
Kobayashi R, Hirayama Y, Kobayashi E, Kubo Y, Hino O . 1995 Nat. Genet. 9: 70–74
Kornberg LJ . 1998 Head Neck 20: 745–752
Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A . 2000 Nat. Cell. Biol. 2: 281–287
Miloloza A, Rosner M, Nellist M, Halley D, Bernaschek G, Hengstschlager M . 2000 Hum. Mol. Genet. 9: 1721–1727
Nellist M, Verhaaf B, Goedbloed MA, Reuser AJ, van Den Ouweland AM, Halley DJ . 2001 Hum. Mol. Genet. 10: 2889–2898
Plank TL, Yeung RS, Henske EP . 1998 Cancer Res. 58: 4766–4770
Potter CJ, Huang H, Xu T . 2001 Cell 105: 357–368
Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P, Narumiya S . 1996 J. Biol. Chem. 271: 13556–13560
Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M . 2000 Mol. Biol. Cell 11: 1709–1725
Sastry SK, Burridge K . 2000 Exp. Cell. Res. 261: 25–36
Schmitz AA, Govek EE, Bottner B, Van Aelst L . 2000 Exp. Cell Res. 261: 1–12
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD . 2000 Nat. Cell. Biol. 2: 249–256
Sinnett-Smith J, Lunn JA, Leopoldt D, Rozengurt E . 2001 Exp. Cell Res. 266: 292–302
Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M . 1997 J. Biol. Chem. 272: 29301–29308
Sullivan EJ . 1998 Chest 114: 1689–1703
Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK . 2001 Cell 105: 345–355
Timpson P, Jones GE, Frame MC, Brunton VG . 2001 Curr. Biol. 11: 1836–1846
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell R, Cheadle J, Jones A, Tachataki M, Ravine D, Sampson J, Reeve M, Richardson P, Wilmer R, Munro C, Hawkins T, Sepp T, Ali J, Ward S, Green A, Yates J, Kwiatkowska J, Henske E, Short M, Haines J, Jozwiak S, Kwiatkowski D . 1997 Science 277: 805–808
van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P . 1998 Hum. Mol. Genet. 7: 1053–1057
Weiner TM, Liu ET, Craven RJ, Cance WG . 1993 Lancet 342: 1024–1025
Wienecke R, Konig A, DeClue JE . 1995 J. Biol. Chem. 270: 16409–16414
Xiao GH, Shoarinejad F, Jin F, Golemis EA, Yeung RS . 1997 J. Biol. Chem. 272: 6097–6100
Yeung RS, Xiao GH, Everitt JI, Jin F, Walker CL . 1995 Mol. Carcinog. 14: 28–36
Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG . 1994 Proc. Natl. Acad. Sci. USA 91: 11413–11416
Yu J, Astrinidis A, Henske EP . 2001 Am. J. Respir. Crit. Care Med. 164: 1537–1540
Acknowledgements
We are grateful to Drs Erica Golemis and Joseph Testa for critical review of this manuscript. This work was supported by NIH grants HL 60746 and DK 51052, and the LAM Foundation (Cincinnati, OH, USA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Astrinidis, A., Cash, T., Hunter, D. et al. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21, 8470–8476 (2002). https://doi.org/10.1038/sj.onc.1205962
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205962
Keywords
This article is cited by
-
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers
Molecular Cancer (2021)
-
RHOA signaling defects result in impaired axon guidance in iPSC-derived neurons from patients with tuberous sclerosis complex
Nature Communications (2021)
-
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Nature Communications (2021)
-
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Orphanet Journal of Rare Diseases (2020)
-
Stability of tuberous sclerosis complex 2 is controlled by methylation at R1457 and R1459
Scientific Reports (2020)